Staphylococcal scalded skin syndrome (SSSS) is a clinical condition primarily affecting infants, elderly individuals, and those with impaired immune systems. It is caused by Staphylococcus aureus and can be replicated by a specific extracellular toxin. The condition is also known as Ritter's disease, bullous impetigo, pemphigus neonatorum, and staphylococcal scarlatiniform rash. A study on the production of exfoliative toxins (ET) from patients with dermatological conditions revealed two identified toxin serotypes: ETA and ETB. There seems to be a correlation between the severity of the disease, the quantity of toxin generated, and whether the toxin is delivered in a localized or systemic manner. The occurrence rate was low, with a significant disparity between children and adults. The primary risk factor in children was young age, while in adults, immunosuppression and consumptive infectious disease were identified. The mortality rate in paediatric patients ranged from 3.6% to 11%, while in adults, it ranged from 40% to 63%. SSSS is a vesiculobullous condition characterized by tenderness, redness, peeling, or blister formation. The best treatment strategy involves a combined approach in specialized intensive care or burn units, with antibiotic treatment being crucial, especially for methicillin-sensitive S. aureus infections. Further research is needed to identify the specific infection site, which can be blood samples, wounds, or ocular exudates. The purpose of this review is to summarize advances in understanding of this serious disorder.